AVTX - CIK 0001534120
Avalo Therapeutics, Inc. trades as AVTX. In its fiscal 2025 annual report the company posted revenue of $59.00K, down 86.6% from the prior year and net income of -$78.26M. This page tracks Avalo Therapeutics, Inc. through 997 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Avalo Therapeutics, Inc.'s revenue declined from $1.15M to $59.00K, a compound annual decline rate of 28.1%. Net profit margin compressed from -1428.6% to -132642.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| Insider trade | 4 | 2026-05-26 |
| SCHEDULE 13G | - | 2026-05-26 |
| Insider trade | 4 | 2026-05-19 |
| SCHEDULE 13G | - | 2026-05-15 |
The largest companies sharing Avalo Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Avalo Therapeutics, Inc. reported revenue of $59.00K for fiscal year 2025, a decrease of 86.6% year over year.
In its latest fiscal year Avalo Therapeutics, Inc. reported a net loss of $78.26M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.